Head-to-head for moms
CoreAge Rx vs Mevo Health
CoreAge Rx and Mevo Health both offer GLP-1 telehealth to mothers, but they make different trade-offs on family-budget value, clinical oversight, price and access. Here they are side-by-side on the Editors' Rating — our six-factor rubric for mothers.
CoreAge Rx
Higher scoreRanked #1 · Grade A
Best for: Mothers who want to know the real monthly cost before the free trial talks them into it — one flat price on semaglutide or tirzepatide, everywhere in the country, with no lock-in.
Visit CoreAge RxMevo Health
Ranked #45 · Grade C
Best for: Mothers who want a genuine oral option on both molecules and value a roster of four named physicians, and who will confirm the real price at their dose before enrolling since only a floor rate is public.
Visit Mevo HealthThe verdict
CoreAge Rx edges out Mevo Health on the Editors' Rating, 94 to 66 (A vs C). Mothers who want to know the real monthly cost before the free trial talks them into it — one flat price on semaglutide or tirzepatide, everywhere in the country, with no lock-in.
Mevo Health is still a genuine option — quotes semaglutide from $199/mo and tirzepatide from $259/mo — both also available as an oral tablet at the same floor price — but only a starting number is published for either molecule, and per-dose pricing above that floor isn't disclosed. Weigh the six factors below against your own priorities.
Side-by-side on the six factors
Both providers scored on the same women's-health rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
| Detail | CoreAge Rx | Mevo Health |
|---|---|---|
| Editors' Rating | 94/100 · A | 66/100 · C |
| Overall rank | #1 | #45 |
| Semaglutide | $99/mo | $199/mo |
| Tirzepatide | $149/mo | $259/mo |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
CoreAge Rx
Ranked #1 · Grade A
What we like
- Flat all-in price that doesn't step up after month one — the number you sign for is the number at the full dose
- Both compounded semaglutide and tirzepatide on a single account, so a molecule switch never resets the budget
- Licensed in all 50 states — care survives a move, a deployment, or a summer at the grandparents'
The caveats
- Not the rock-bottom sticker price — a bare teaser tier elsewhere can look cheaper for exactly one month
- Compounded only; no FDA-approved brand Wegovy or Zepbound if that is what you and your clinician want
- A general metabolic program, not a dedicated women's or maternal-health clinic
Mevo Health
Ranked #45 · Grade C
What we like
- Both molecules are available as an oral tablet at the same floor price as the injection — a genuine needle-free option on both drugs
- Four named physicians on staff (Dr. David Wasef, head of the Mevo Provider Network; Drs. Frank Suppa, Andrew Sakla and Constantin Chikando), with specialties disclosed
- LegitScript seal confirmed present on the homepage, contact page and footer
The caveats
- Only a floor ("as low as") price is published for either molecule — there's no visible per-dose ladder, so the real price at a higher dose isn't disclosed up front
- States served aren't listed anywhere on the site
- Two of its four named physicians, Dr. Wasef and Dr. Suppa, also appear on Vytora Health's and Ondra Health's sites — a standard moonlighting pattern across DTC telehealth brands, not evidence of a shared company, but worth knowing before assuming the practice is exclusive to Mevo
We may earn a referral fee if you sign up through a link on this page, at no extra cost to you — and it has no bearing on which provider scores higher. Pricing, states and verification reflect each provider's public disclosures at last review; the Editors' Rating is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Keep comparing CoreAge Rx and Mevo Health against other providers we review for mothers.
Or browse the full comparison hub.